ライフサイエンスコーパス: trials have been

1 ing platform, only 15% of these trials and 29% of phase 3/4 trials have been accessed by investigators thus far, and a ne

2 No randomized controlled trials have been completed to confirm that physical activity

3 Recently, a number of phage therapy phase I and II safety trials have been concluded, showing no notable safety concern

4 Few cardiovascular outcomes trials have been conducted for obesity treatments.

5 Accordingly, Dex-based phase I and II clinical trials have been conducted in advanced malignancies, showing

6 No randomized trials have been conducted to directly compare radiotherapy (

7 observational although some randomised, placebo-controlled trials have been conducted with omega 3 PUFAs and one with vi

8 -resistant bipolar depression, but no randomized controlled trials have been conducted, to the authors' knowledge.

9 Moreover, none of the published randomized trials have been designed to answer this question.

10 Unfortunately, these trials have been designed without a strong foundational knowl

11 However, clinical trials have been disappointing in part to dose-limiting hyper

12 atment of children in high-income countries, no substantive trials have been done of the interventions adapted for use in

13 Few high quality treatment trials have been done on psychiatric disorders in prisoners.

14 However, physicians rarely intervene and no trials have been done on the subject.

15 No randomised controlled trials have been done to identify the optimum treatment for t

16 No large trials have been done to investigate the efficacy of an inter

17 Many clinical trials have been done with either naked oncolytic Ad or combi

18 An unprecedented number of trials have been done, initiated, or are planned to test new

19 cirrhosis, but no adequately powered randomised controlled trials have been done.

20 d to improvement in negative symptoms and function, but few trials have been done.

21 n resistance (IR); however, results from human intervention trials have been equivocal.

22 ocardial injury; however, the benefits observed in clinical trials have been generally less consistent.

23 cardiovascular disease, but data from randomized controlled trials have been inconclusive.

24 n prospective studies, but results from randomized clinical trials have been inconsistent.

25 es have shown that placebo response rates in antidepressant trials have been increasing since the 1970s.

26 Causes of placebo effects in antidepressant trials have been inferred from observational studies and meta

27 ive in specific Ph-like ALL subsets, and precision medicine trials have been initiated for this high-risk ALL subset.

28 In contrast, relatively few clinical trials have been initiated using specific inhibitors that inh

29 In view of these results, further clinical trials have been initiated, and sFLT1 will be investigated as

30 However, results of antioxidant-based trials have been largely negative.

31 Existing clinical trials have been limited by short duration, low doses of vita

32 Dietary clinical trials have been limited by their inability to include a plac

33 Results from clinical trials have been mixed so far.

34 culties associated with integrating imaging biomarkers into trials have been neglected compared with inclusion of tissue

35 Over the past 1.5 decades, numerous stem cell trials have been performed in patients with cardiovascular di

36 A number of controlled clinical trials have been performed to show important biologic effects

37 Several breast cancer trials have been performed with the PET tracers (18)F-FDG, 3'

38 nsidered to have high-risk cSCC, but no randomized clinical trials have been performed.

39 ncytial virus (RSV) vaccines that have advanced to clinical trials have been produced in Vero cells.

40 the spectrum of HF, preliminary results from many phase II trials have been promising but are frequently followed by uns

41 Although results of intravenous iron repletion trials have been promising, regularly treating patients with

42 For bevacizumab only two clinical trials have been published and a head-to-head comparison is l

43 ed routinely to treat depression, yet no placebo-controlled trials have been published in this population to our knowledg

44 yet been conclusively determined as no randomized clinical trials have been published on this issue, and their effective

45 e was provided, the results of early phase 1 and 2 clinical trials have been quite disappointing to date, and toxicities

46 Although risk reductions observed in randomized trials have been relatively consistent across series, the abs

47 However, trials have been relatively scarce and limited in sample size

48 admission to hospital in patients with psychosis, but these trials have been short (11-12 months).

49 Model systems and clinical trials have been slow to address the clinical questions that

50 elief, the average placebo response rates in antidepressant trials have been stable for more than 25 years.